The Role of LINC01569/miR‐4722‐5p/RAB14 Regulatory Axis in Chronic Obstructive Pulmonary Disease‐Related Inflammation and Its Clinical Value Analysis
简介:
- 作者: Guangfei Xu, Na Wang, Jianying Wang
- 杂志: Journal of Biochemical and Molecular Toxicology
- Doi: https://www.doi.org/10.1002/jbt.70684
- 出版日期: 2026/1/15
摘要
Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disorder. Its prevention and management have become increasingly challenging owing to subtle and easily overlooked early symptoms, warranting the exploration of detection markers. Hence, this study aimed to explore COPD-related competitive endogenous RNA (ceRNA) mechanisms with notable predictive value by leveraging bioinformatics methods. Herein, Gene Expression Omnibus, lncRNASNP2, and miRDB were used to construct a COPD-related ceRNA network, which was then assessed through Kyoto Encyclopedia of Gene and Genomes pathway analysis. The targeting relationship of identified axis was confirmed through RNA pull-down and dual-luciferase reporter assays. In total, 106 patients with stable COPD and 98 patients with acute exacerbation COPD (AECOPD) were enrolled. Binary logistic regression and receiver operating characteristic curve analyses were performed to evaluate the clinical significance of the identified axis. Additionally, its role in COPD-related inflammation was investigated in BEAS-2B cells treated with cigarette smoke extract (CSE). A potential ceRNA mechanism was identified involving LINC01569, miR-4722-5p, and RAB14, where LINC01569 overexpression promoted RAB14 expression by competitively binding to miR-4722-5p. Both LINC01569 and RAB14 were highly expressed in AECOPD, making them risk factors of COPD (odds ratio [OR] = 5.100 and 8.076, respectively), with their area under the curve (AUC) values for predicting disease progression being 0.878 and 0.822, respectively. In contrast, miR-4722-5p acted as a potential protective factor (OR = 0.448), with an AUC of 0.724 for predicting AECOPD occurrence. Their serum expression strongly correlated with inflammatory markers. In CSE-treated BEAS-2B cells, silencing LINC01569 upregulated miR-4722-5p, thereby suppressing RAB14 expression and reducing pro-inflammatory factor production. Altogether, the LINC01569/miR-4722-5p/RAB14 regulatory axis represents a potential ceRNA mechanism influencing COPD progression. It demonstrates significant predictive value for disease development and plays a crucial role in COPD-associated inflammatory processes.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。